June 21, 2021
7 min watch
Save
Personalized therapies, other breakthroughs yield great potential in AML
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about breakthroughs in therapy that he hopes to see in the future.
Click here to watch more from the AML Awareness video series.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gerber served as a principal investigator on a study funded by Janssen evaluating a CD123 bispecific agent and holds a patent (but has not collected royalties) on a leukemia stem cell detection assay for AML.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.